Rare diseases
Investigational molecules
Locations
26 Rue D Ulm, 75005 Paris, France
Institut Curie - Site Paris in Paris, France specialises in clinical trials of conditions such as Non-small cell lung cancer, Breast cancer, Neoplasm, Squamous cell carcinoma of head and neck, and other specialisations. This site conducts important research.
This research site focuses on cancer studies across several neoplastic diseases, with trials aimed at improving treatment outcomes, testing new anti-cancer combinations, and refining supportive approaches for patients with advanced or hard-to-treat tumors.
Overall, the clinical research program at Institut Curie is centered on finding more effective and better-tolerated treatments for aggressive cancers, while also examining how treatment selection can improve outcomes in metastatic disease and after surgery.
Clinical trials currently enrolling participants at this site.
A study to evaluate the safety and effectiveness of HLX43 in patients with advanced non-small cell lung cancer
FranceStudy of BNT327 and a drug combination for patients with untreated metastatic or locally recurrent triple-negative breast cancer
FranceA Study of Darovasertib Before Surgery or Radiation Therapy for Patients with Early-Stage Uveal Melanoma That Has Not Spread
FranceStudy on the Safety and Effectiveness of Trastuzumab Deruxtecan vs. Palbociclib-Based Drug Combination for Advanced HR-Positive, HER2-Low Breast Cancer Patients
FranceStudy on the Safety and Effectiveness of BNT327 with Chemotherapy for Patients with Non-Small Cell Lung Cancer
FranceStudy on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy
FranceFirst-line treatment of metastatic non‑small cell lung cancer with high PD‑L1 expression: ivonescimab versus pembrolizumab
FranceA Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment
FranceStudy of drug combinations including cisplatin, carboplatin, doxorubicin, fluorouracil, vincristine, etoposide, irinotecan, gemcitabine, oxaliplatin and sorafenib for children with hepatoblastoma or hepatocellular carcinoma
FranceStudy of Amivantamab, Lazertinib, and Pemetrexed for Patients with Advanced or Metastatic Solid Tumors, Including EGFR-Mutated Non-Small Cell Lung Cancer
FrancePhase 2 Study Evaluating Safety and Efficacy of Belzutifan in Adults with Solid Tumors
FrancePhase 2 Study of Imzokitug with drug combination as First‑Line Treatment for Adults with Locally Advanced or Metastatic Non‑Small Cell Lung Cancer (NSCLC)
FranceMove up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.
